Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal
PLOS Neglected Tropical Diseases · 21.01.2026 · 20 (1) · e0013242
DOI: 10.1371/journal.pntd.0013242 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 21.01.2026. Verfasst von Dipesh Tamrakar und 18 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Disease Research and Surveillance, Dhulikhel Hospital Kathmandu University Hospital, Dhulikhel, Nepal. Hauptthemen laut MEDLINE: Typhoid Fever, Typhoid-Paratyphoid Vaccines, COVID-19. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background
While typhoid conjugate vaccines (TCV) offer promise for reducing risk in endemic settings, their population-level impact remains unclear. In 2022, Nepal introduced TCV nationally on the heels of the COVID-19 pandemic, which disrupted healthcare services, surveillance, and potentially typhoid transmission dynamics, complicating vaccine impact evaluation. We investigated the impact of TCV introduction amid shifting typhoid burden during the pandemic.
Methods
We analyzed blood culture data from four Kathmandu Valley health facilities, comparing culture positivity for Salmonella Typhi across three periods: pre-pandemic (January 2018-March 2020); pandemic, pre-vaccine introduction (April 2020-March 2022); post-vaccine introduction (April 2022-April 2024). We used multivariable logistic regression to assess S. Typhi positivity, adjusting for month and site, stratified by TCV-eligible children and older, TCV-ineligible populations.
Results
Between January 2018 and April 2024, 62,236 blood cultures were performed. S. Typhi blood culture positivity decreased from 2.11% pre-pandemic to 0.59% during the pandemic (p < 0.001) and remained low at 0.69% after TCV introduction. Among TCV-eligible children (15 months to 15 years), odds of S. Typhi positivity during the pandemic were 47% lower than the pre-COVID period (aOR 0.53, 95% CI 0.29-0.90) and continued to decrease by 75% post-TCV introduction (aOR 0.25, 95% CI 0.11-0.55). In contrast, among vaccine-ineligible individuals (≥16 years), odds of positivity during the pandemic were 77% lower than the pre-COVID period (aOR 0.23, 95% CI 0.16-0.31) but increased by 59% following TCV rollout (aOR 1.59, 95% CI 1.14-2.27). Sensitivity analyses restricted to pathogen-positive cultures yielded similar results.
Conclusion
S. Typhi blood culture positivity declined sharply during the pandemic before TCV introduction. The subsequent rollout of TCV substantially reduced typhoid burden in vaccine-eligible children; however, rising cases among older, vaccine-ineligible populations following the relaxation of pandemic measures highlights the need for additional control measures such as improved water and sanitation infrastructure and broader age eligibility for typhoid vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Infectious Disease Research and Surveillance, Dhulikhel Hospital Kathmandu University Hospital, Dhulikhel, Nepal.
- Department of Community Medicine, Kathmandu University School of Medical Sciences, Dhulikhel, Nepal.
- Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
- Microbiology Unit, Department of Pathology, Kathmandu Model Hospital, Kathmandu, Nepal.
- Department of Pathology, Bir Hospital, Kathmandu, Nepal.
- Helping Hands Community Hospital, Kathmandu, Nepal.
ORCID-Profile: Esther Jung, Jason R Andrews
Förderung
- Bill and Melinda Gates Foundation
Zitieren
APA
Tamrakar, D., Naga, S. R., Jung, E., Shrestha, B., Bista Roka, P., Pokharel, R., Shahi, S. B., Bajracharya, A. T., Mahadup, S. K., Katuwal, N., Doyle, K., Seidman, J. C., Carter, A. S., Luby, S. P., Bogoch, I. I., Aiemjoy, K., Garrett, D. O., Shrestha, R., & Andrews, J. R. (2026). Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal. PLOS Neglected Tropical Diseases, 20(1), e0013242. https://doi.org/10.1371/journal.pntd.0013242
Vancouver
Tamrakar D, Naga SR, Jung E, Shrestha B, Bista Roka P, Pokharel R, et al. Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal. PLOS Neglected Tropical Diseases. 2026;20(1):e0013242. doi:10.1371/journal.pntd.0013242
BibTeX
@article{Tamrakar2026,
author = {Tamrakar, Dipesh and Naga, Shiva Ram and Jung, Esther and Shrestha, Basudha and Bista Roka, Pratibha and Pokharel, Rabin and Shahi, Sabin Bikram and Bajracharya, Aarjya Tara and Mahadup, Surendra K and Katuwal, Nishan and Doyle, Kate and Seidman, Jessica C and Carter, Alice S and Luby, Stephen P and Bogoch, Isaac I and Aiemjoy, Kristen and Garrett, Denise O and Shrestha, Rajeev and Andrews, Jason R},
title = {Impact of the COVID-19 pandemic and typhoid conjugate vaccine introduction on typhoid fever in Nepal},
journal = {PLOS Neglected Tropical Diseases},
year = {2026},
volume = {20},
number = {1},
pages = {e0013242},
doi = {10.1371/journal.pntd.0013242}
}
EUVIMED